Physician profile
Christopher W Daniel
NPI 1073168191
$514.28
in general payments reported to CMS, 2019-2025
14 companies · $20.62 in 2025
The $20.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $163 · 2023: $132 · 2024: $14.96 · 2025: $20.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $167.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $129.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $77.08 | 2021-2023 | Trelegy Ellipta |
| Abbott Laboratories | $46.23 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $40.40 | 2022 | |
| Boston Scientific Corporation | $37.13 | 2022 | |
| Lilly USA, LLC | $32.70 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $28.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $22.58 | 2022 | |
| Neurocrine Biosciences, INC. | $20.62 | 2025 | |
| Philips North America LLC | $20.09 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.25 | 2023 | Xifaxan |
| Amgen INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.